跳至主要内容
临床试验/CTRI/2022/08/045044
CTRI/2022/08/045044
尚未招募
未知

A pharmacogenomics study to identify genetic risk factors for development of Ethambutol optic neuropathy

Duke NUS Program Grant Award0 个研究点目标入组 0 人待定

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
未指定
发起方
Duke NUS Program Grant Award
状态
尚未招募
最后更新
3年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
3年前
研究类型
Observational

研究者

发起方
Duke NUS Program Grant Award

入排标准

入选标准

  • 1\)Patients newly started on anti tuberculosis treatment will be included in the study.
  • 2\)Each patient will be followed up until the duration of treatment is completed depending on the treatment regime.
  • 3\)Once follow up is completed for all recruited patients, EON(Ethambutol optic neuropathy) will be defined by visual acuity assessment to test the inability of the patient to see clearly in dim light post treatment.
  • 4\)Patients who develop EON during the study period will be classified as cases and treated patients who did not develop EON will be classified as controls.

排除标准

  • Patients with previous optic neuropathy of other causes and retinal pathology causing vision impairment will be excluded

结局指标

主要结局

未指定

相似试验